ClinicalTrials.gg
CompletedNCT01421667Updated Nov 28, 2016Results posted

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase 2 interventional study of brentuximab vedotin and rituximab in Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 34 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2016-11-28.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer — none open to participants now, 1 under way, 1 of them phase 3. Lymphoma, Large B-Cell, Diffuse · Pfizer.

Enrollment
5th of 25
176 · median 58
Started
2011
with 2 others
Phase 2
9 of 25
none open now
Registered
7th of 25
by date

Among the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 9 in phase 2, and was the 7th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Lymphoma, Large B-Cell, Diffuse by Pfizer as a file.
02

Study summary

This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).

03

Conditions studied

  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell

Keywords

  • Lymphoma, Large B-Cell, Diffuse
  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin
  • Monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, T-Cell
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 176 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed NHL (DLBCL only for Parts B and C)
  • disease following at least 1 prior systemic therapy
  • of at least 1.5 cm as documented by CT
  • (ECOG) performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • History of another primary invasive that has not been in remission for at least 3 years
  • Current diagnosis of systemic or cutaneous anaplastic large cell lymphoma or mycosis fungoides
  • B cell lymphoma previously treated with only single-agent rituximab (for patients receiving brentuximab vedotin only) or as monotherapy
  • Known cerebral/meningeal disease
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin+rituximab

    Drug: brentuximab vedotin · Drug: rituximab

  • Experimental
    Brentuximab vedotin

    Drug: brentuximab vedotin

Interventions

  • 1.8 mg/kg every 3 weeks by IV infusion

    Also known as: Adcetris; SGN-35

  • 375 mg/m2 every 3 weeks by IV infusion

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy

    Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 3 years

  2. Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab

    Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: Up to 3 years

Secondary outcomes

  1. Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab

    Percentage of participants treated with brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 3 years

  2. Complete Remission (CR) Rate by Investigator

    Percentage of participants treated with brentuximab vedotin monotherapy or brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 3 years

  3. Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

    Duration of complete remission (CR) or partial remission (PR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 3 years

  4. Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

    Duration of complete remission (CR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to approximately 3 years

  5. Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

    Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause

    Time frame: Up to approximately 3 years

  6. Correlation Between Antitumor Activity of Brentuximab Vedotin Monotherapy and CD30 Expression

    Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), or stable disease (SD, no new sites and no change in size of previous lesions) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma. Patients are grouped by CD30-positivity or CD30u (undetectable CD30).

    Time frame: Up to 3 years

  7. Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Monotherapy

    Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

    Time frame: Up to 3 years

  8. Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)

    End of infusion concentration of ADC following the first dose of brentuximab vedotin

    Time frame: 1 day

  9. Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)

    Trough concentration of ADC from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  10. Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)

    Maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  11. Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)

    Time of maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin

    Time frame: 3 weeks

  12. Baseline Soluble CD30 Expression

    Serum concentration of soluble CD30 before first dose of brentuximab vedotin

    Time frame: Baseline

08

Results

Posted Oct 13, 2016

Participant flow

Aug 2011 - Jun 2015

Participant flow — Overall Study
MilestoneCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+R
Started35685316
Completed35665115
Not completed0221
Withdrew: Withdrawal by subject0121
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryObjective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy

Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy
percentage of participantsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BV
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Monotherapy41 (24.6 to 59.3)26 (9.1 to 51.2)44 (29.5 to 58.8)31 (18.7 to 45.1)
PrimaryAdverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab

Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
Up to 3 years
Reported as:
Number · participants
Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Plus Rituximab
participantsCD30+ DLBCL, BV+R
Any TEAE16
TEAE Related to Study Drug15
TEAE With Severity Grade >/=39
Discontinued Treatment Due to Adverse Event2
Serious Adverse Event3
Serious Adverse Event Related to Study Drug3
Deaths (Within 30 Days of Last Dose)1
Chemistry Laboratory Abnormalities >/=Grade 31
Hematology Laboratory Abnormalities >/=Grade 37
SecondaryObjective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab

Percentage of participants treated with brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab
percentage of participantsCD30+ DLBCL, BV+R
Objective Response Rate (ORR) by Investigator With Brentuximab Vedotin Plus Rituximab50 (21.1 to 78.9)
SecondaryComplete Remission (CR) Rate by Investigator

Percentage of participants treated with brentuximab vedotin monotherapy or brentuximab vedotin plus rituximab who achieved a best response of complete remission (CR, disappearance of all evidence of disease) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 3 years
Reported as:
Number · percentage of participants
Complete Remission (CR) Rate by Investigator
percentage of participantsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+R
Complete Remission (CR) Rate by Investigator24 (10.7 to 41.2)16 (3.4 to 39.6)19 (8.9 to 32.6)12 (4.4 to 23.4)17 (2.1 to 48.4)
SecondaryDuration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

Duration of complete remission (CR) or partial remission (PR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
monthsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BV
Duration of Objective Response With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis7.6 (1.3 to 36.1)1.6 (1.4 to 34)4.7 (0 to 22.7)4.7 (0.5 to 11.6)
SecondaryDuration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

Duration of complete remission (CR), defined as time of initial response until disease progression or death. Response criteria per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
monthsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BV
Duration of Complete Remission With Brentuximab Vedotin Monotherapy by Kaplan-Meier AnalysisNA (1.8 to NA)7.2 (1.6 to 34)NA (2.2 to NA)11.6 (1.4 to 11.6)
SecondaryProgression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis

Progression-free survival, defined as time from start of study treatment to disease progression per investigator or death due to any cause

Time frame:
Up to approximately 3 years
Reported as:
Median · months
Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis
monthsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BV
Progression-Free Survival With Brentuximab Vedotin Monotherapy by Kaplan-Meier Analysis2.5 (0.3 to 37.4)2.9 (0.6 to 36.3)4.0 (0.6 to 24.0)1.4 (0.4 to 15.6)
SecondaryCorrelation Between Antitumor Activity of Brentuximab Vedotin Monotherapy and CD30 Expression

Percentage of participants treated with brentuximab vedotin monotherapy who achieved a best response of complete remission (CR, disappearance of all evidence of disease), partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites), or stable disease (SD, no new sites and no change in size of previous lesions) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma. Patients are grouped by CD30-positivity or CD30u (undetectable CD30).

Time frame:
Up to 3 years
Reported as:
Number · percentage of participants
Correlation Between Antitumor Activity of Brentuximab Vedotin Monotherapy and CD30 Expression
percentage of participantsCD30+ T-Cell NHL, BVCD30+ Other B-Cell NHL, BVCD30+ DLBCL, BVCD30u DLBCL, BV
Complete Remission (CR)24 (10.7 to 41.2)16 (3.4 to 39.6)19 (8.9 to 32.6)12 (4.4 to 23.4)
Partial Remission (PR)18 (6.8 to 34.5)11 (1.3 to 33.1)25 (13.6 to 39.6)19 (9.6 to 32.5)
Disease Control Rate (CR+PR+SD)59 (40.7 to 75.4)63 (38.4 to 83.7)69 (53.7 to 81.3)42 (28.7 to 56.8)
SecondaryAdverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Monotherapy

Counts of participants who had treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on Study SGN35-012). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life-threatening/disabling, 5=fatal). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.

Time frame:
Up to 3 years
Reported as:
Number · participants
Adverse Events by Severity, Seriousness, and Relationship to Treatment With Brentuximab Vedotin Monotherapy
participantsCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Any TEAE326652
TEAE Related to Study Drug286239
TEAE With Severity Grade >/=3235237
Discontinued Treatment Due To Adverse Event674
Serious Adverse Event153422
Serious Adverse Event Related to Study Drug5157
Deaths (Within 30 Days of Last Dose)356
Chemistry Laboratory Abnormalities >/= Grade 381610
Hematology Laboratory Abnormalities >/= Grade 3113121
SecondaryBrentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)

End of infusion concentration of ADC following the first dose of brentuximab vedotin

Time frame:
1 day
Reported as:
Geometric mean · ug/mL
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)
ug/mLCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi) (Cycle 1)35.6 ± 2540.0 ± 2940.1 ± 43
SecondaryBrentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)

Trough concentration of ADC from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · ug/mL
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)
ug/mLCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough) (Cycle 1)0.44 ± 1130.91 ± 1190.86 ± 94
SecondaryMaximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)

Maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Geometric mean · ng/mL
Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)
ng/mLCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE) (Cycle 1)4.71 ± 634.66 ± 883.95 ± 74
SecondaryTime to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)

Time of maximum serum concentration of MMAE from 0 to 21 days following the first dose of brentuximab vedotin

Time frame:
3 weeks
Reported as:
Median · days
Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)
daysCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Time to Maximum Concentration (Tmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)1.90 (0.88 to 6.89)1.91 (0.91 to 20.90)1.94 (0.93 to 19.8)
SecondaryBaseline Soluble CD30 Expression

Serum concentration of soluble CD30 before first dose of brentuximab vedotin

Time frame:
Baseline
Reported as:
Median · ng/mL
Baseline Soluble CD30 Expression
ng/mLCD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BV
Baseline Soluble CD30 Expression1005.4 (89.4 to 26426.6)229.4 (33.2 to 21277.7)140.4 (53.4 to 1695.9)

Adverse events

Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD30+ NHL (T-Cell and B-Cell), BV—49/103 (47.6%)96/103 (93.2%)
CD30u DLBCL, BV—22/53 (41.5%)48/53 (90.6%)
CD30+ DLBCL, BV+R—3/16 (18.8%)15/16 (93.8%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventCD30+ NHL (T-Cell and B-Cell), BVCD30u DLBCL, BVCD30+ DLBCL, BV+R
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/1036/530/16
PyrexiaGeneral disorders9/1030/530/16
PneumoniaInfections and infestations8/1033/530/16
Escherichia urinary tract infectionInfections and infestations0/1030/531/16
Febrile neutropeniaBlood and lymphatic system disorders3/1032/531/16
HyponatremiaMetabolism and nutrition disorders1/1031/531/16
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1030/531/16
Mental status changesPsychiatric disorders0/1030/531/16
Sinus tachycardiaCardiac disorders0/1031/531/16
Toxic epidermal necrolysisSkin and subcutaneous tissue disorders0/1030/531/16
Most frequent other events
Showing 10 of 40
Most frequent other events
EventCD30+ NHL (T-Cell and B-Cell), BVCD30u DLBCL, BVCD30+ DLBCL, BV+R
NauseaGastrointestinal disorders28/10317/538/16
FatigueGeneral disorders43/10317/534/16
NeutropeniaBlood and lymphatic system disorders31/10313/536/16
VomtingGastrointestinal disorders19/10311/536/16
Peripheral sensory neuropathyNervous system disorders33/10314/536/16
DiarrheaGastrointestinal disorders33/1039/534/16
PyrexiaGeneral disorders22/10312/535/16
ConstipationGastrointestinal disorders19/10315/532/16
ChillsGeneral disorders11/1033/534/16
PruritusSkin and subcutaneous tissue disorders13/1035/534/16

Baseline characteristics

All participants who received treatment.

Age, Continuous
Age, Continuous(years)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Median64 (33 to 83)57 (16 to 85)65 (21 to 91)62 (22 to 78)63 (16 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Female82927468
Male27392612104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Hispanic or Latino337114
Not Hispanic or Latino32654615158
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
American Indian or Alaska Native01102
Asian13408
Native Hawaiian or Other Pacific Islander00101
Black or African American564015
White29554115140
More than one race03216
Unknown or Not Reported00000
Pathological Diagnosis
Pathological Diagnosis(participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Diffuse Large B-Cell Lymphoma (DLBCL)0435316112
Epstein-Barr Virus-Associated DLBCL of Elderly05005
Follicular Lymphoma03003
Gray Zone Lymphoma06006
Primary Mediastinal B-Cell Lymphoma06006
Post-Transplant Lymphoproliferative Disorder03003
Plasmablastic Lymphoma01001
T-Cell Rich B-Cell Lymphoma01001
Angioimmunoblastic T-cell Lymphoma1300013
Peripheral T-Cell Lymphoma Not Otherwise Specified2200022
Transformed Disease from Prior Non-Hodgkin Lymphoma
Transformed Disease from Prior Non-Hodgkin Lymphoma(participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Yes11411531
No34544211141
Disease Stage
Disease Stage(participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Stage I24118
Stage II2127324
Stage III131711647
Stage IV143133684
Unknown44109
Bulky Disease (≥5 cm on at least one baseline index lesion)
Bulky Disease (≥5 cm on at least one baseline index lesion)(participants)CD30+ T-Cell NHL, BVCD30+ B-Cell NHL, BVCD30u DLBCL, BVCD30+ DLBCL, BV+RTotal
Yes52735471
No30411812101

4 further baseline measures are reported on the registry.

09

Study locations

34 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • City of Hope
    Duarte, California 91010-3000, United States
  • PMK Medical Group Inc., DBA Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • Stanford Cancer Center
    Stanford, California 94305-5821, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Cancer Specialists of North Florida - St. Augustine
    St. Augustine, Florida 32086, United States
  • Emory Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637-1470, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Minnesota Oncology Hematology P.A.
    Minneapolis, Minnesota 55404, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Columbia University Medical Center
    New York, New York 10019, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Cleveland Clinic, The
    Cleveland, Ohio 44195, United States
  • Willamette Valley Cancer and Research / USOR
    Eugene, Oregon 97401, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • St. Francis Hospital
    Greenville, South Carolina 29605, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230, United States
  • Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology-Southwest Fort Worth
    Fort Worth, Texas 76132, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4003, United States
  • Texas Oncology - Seton Williamson
    Round Rock, Texas 78665, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Swedish Cancer Institute Medical Oncology
    Edmonds, Washington 98026, United States
  • Seattle Cancer Care Alliance / University of Washington Medical Center
    Seattle, Washington 98109, United States
  • Northwest Cancer Specialists, P.C.
    Vancouver, Washington 98684, United States
  • British Columbia Cancer Agency - Vancouver Centre
    Vancouver, British Columbia V5Z 4E6, Canada
10

References and documents

Publications

  • Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20. PubMed 24652992 ↗
  • Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8. PubMed 25573987 ↗
  • Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20. PubMed 27868471 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2011
First posted
Aug 23, 2011
Start
Aug 2011
Primary completionActual
Jun 2015
CompletionActual
Jun 2015
Results first posted
Oct 13, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01421667
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 23, 2011
Start date
Aug 2011
Primary completion
Jun 2015
Completion
Jun 2015
Results posted
Oct 13, 2016
Last update
Nov 28, 2016

Study contacts

Corinna Palanca-Wessels, MD, PhD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion